Description
How This Works
Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake[3][10]. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing[6][11].
Potential Benefits & Side Effects
Observations from phase 2 and phase 3 clinical trials.
- Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo[4].
- Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone[5][12].
- Dose‑dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg)[4].
- Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild‑to‑moderate and transient[4][5]. Gradual titration helps minimize these effects.
- Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Lifestyle Factors
Complementary strategies for optimal outcomes.
- Pair with a balanced, protein‑forward diet tailored to individual energy needs.
- Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
- Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
- Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.
BRL R$
Reviews
There are no reviews yet.